A study following 43,994 people for an average of 10.5 years observed liver-cancer risks about twice as high with metabolic dysfunction-associated steatotic liver disease, 7.9 times as high with combined metabolic and alcohol-related disease, and 12 times as high with alcohol-related liver disease, compared with no fatty liver. These are category-specific relative associations, not personal absolute probabilities or proof of alcohol’s isolated causal effect. Review alcohol exposure and metabolic health with a clinician to determine management and surveillance instead of treating all fatty liver as one risk category.